Compare HCA Health Inc (HCA) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HCA Health Inc vs Organon & Co. Common Stock — how do they compare? HCA Health Inc trades at $475 (market cap $99.75B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: HCA Health Inc is far larger — about 27.6× Organon & Co. Common Stock's market cap, and HCA Health Inc pays the higher dividend (0.68%). Which is the better fit depends on your goals — on Pluang, investors hold HCA Health Inc for 76 Days and Organon & Co. Common Stock for 0 Days on average.
| HCA | OGN | |
|---|---|---|
Market Cap | $99.75B | $3.62B |
Volume | 1,083,231 | 2,892,999 |
Sector | Health | Health |
52-Week High | $545.13 | $13.81 |
52-Week Low | $361.32 | $5.70 |
Typical Hold Time | 76 Days | 0 Days |
Enterprise Value | $150.29B | $11.04B |
Dividend Yield | 0.68% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare's stock trades at $470.44, up 2.58% today, with a bullish technical outlook and strong earnings beats in recent quarters. Revenue grew to $75.60B in 2025, with a net income margin of 8.77%, while the P/E ratio of 15.45 suggests reasonable valuation. Recent news includes an upcoming Q3 2026 earnings call and ongoing legal investigations, creating mixed sentiment.
The outlook is positive due to consistent earnings performance and analyst buy ratings, but risks include high debt levels and regulatory scrutiny. Investment opportunity lies in operational efficiency and demand growth, though investors should monitor legal developments and debt management.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
